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Abstract 
Multiple myeloma (MM) is thrombogenic as a consequence of multiple hemostatic 
effects. Thalidomide is an effective treatment; however, it has been associated with an 
increased risk of thromboembolic events including pulmonary hypertension (PH). PH in 
the absence of thromboembolic events has also been described in some patients with 
MM during thalidomide treatment. We experienced occurrence of PH in a MM patient 
during treatment with thalidomide. A 79-year-old woman was diagnosed with IgG 
lambda MM and was started on thalidomide treatment. About a month later, she 
presented with asthenia, palpitation and dyspnoea on exertion and was hospitalized. An 
echocardiography revealed severe PH (systolic pulmonary artery pressure 75 mm Hg) 
without paradoxic movement of ventricular septum or right ventricular dysfunction 
signs; a previous echocardiography was normal. Pulmonary computed tomography and 
perfusion scan were negative for pulmonary embolism. Based on the hypothesis of a 
pharmacological pathogenesis, thalidomide was promptly interrupted. About a month 
later, she was hospitalized for further investigations. Physical examination documented 
absence of dyspnoea or other respiratory signs, and echocardiography showed normal 
right ventricular function and normal pulmonary artery pressure. As in the cases reported 
in the literature, we suggest a possible direct correlation between thalidomide and PH, 
since in all cases a rapid decrease of pulmonary artery pressure after thalidomide 
discontinuation was observed. 
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Introduction 
Multiple myeloma (MM) is thrombogenic as a consequence of multiple hemostatic 
effects, including elevated interleukin-6 levels, procoagulant antibody formation, 
paraprotein interference with fibrin structure, activated protein C resistance and 
endothelial damage [1]. 
Thalidomide is an effective treatment both in advanced MM and as first-line therapy in 
combination with dexamethasone or other cytotoxic chemotherapy [2]; it has been 
associated with an increased risk of thromboembolic events including pulmonary 
hypertension (PH) [3, 4]. PH in the absence of thromboembolic events has also been 
described in 3 patients with MM during thalidomide treatment [5–7] and in a pilot study 
[1]. We also experienced occurrence of PH in a MM patient during treatment with 
thalidomide. 
Case Presentation 
In September 2010, a 79-year-old woman was diagnosed with IgG lambda MM evolved from 
monoclonal gammopathy of unknown significance (MGUS). In April 2011, the patient was started on 
thalidomide (50 mg daily) and prednisone treatment. About a month later, she presented with asthenia, 
palpitation and dyspnoea on exertion and was hospitalized.  
Physical examination revealed mild tachypnea (20 breaths/min) and tachyarrhythmia. Cyanosis and 
edema of the lower extremities were not found. ECG showed tachyarrhythmia with atrial fibrillation 
(140 beats/min). Within 24 h, a sinus rhythm was restored with atenolol. A blood sample analysis 
yielded the following results: NT-pro-BNP 3,021 ng/l (normal value <450), D-dimer 519 ng/ml (normal 
value <300), and T-troponin 37.2 ng/l (normal value <14). Blood arterial gas analysis parameters were: 
pH 7.49, pO2 70.2 mm Hg, pCO2 25.1 mm Hg, HCO3
– 19.2 mmol/l, SatO2 95.7%, pO2/FiO2 336 mm Hg. 
An echocardiography performed a few days later showed severe PH (systolic pulmonary artery 
pressure 75 mm Hg) with mild tricuspid insufficiency without paradoxic movement of ventricular 
septum or right ventricular dysfunction signs, and normal left ventricular function. A previous 
echocardiography done in 2008 was normal. Pulmonary computed tomography and perfusion scan 
were negative for pulmonary embolism. Functional lung investigations showed severe oxygen 
desaturation in a 6-min-walk test. No COPD history was present. Connective tissue disease was also 
excluded by further examination. Based on the hypothesis of a pharmacological pathogenesis, 
thalidomide was promptly interrupted. The patient was sent to the Center for Pulmonary Hypertension 
(Policlinico San Matteo, Pavia, Italy) for further investigations. 
In June 2011 (about a month later), she was hospitalized. Physical examination revealed absence of 
dyspnoea or other respiratory signs. Sinus rhythm on ECG and echocardiography showed normal right 
ventricular function and normal pulmonary artery pressure. A clinical control in July 2011 confirmed 
absence of symptoms, and showed a peripheral SatO2 of 97% and a pulmonary artery pressure of 26 mm 
Hg. 
Discussion 
As in the 3 cases reported in the literature [5–7], we suggest a possible direct 
correlation between thalidomide and PH, since in all cases a rapid decrease of pulmonary 
artery pressure after thalidomide discontinuation was observed. Furthermore, in the pilot 
study of Lafaras et al. [1], 4 of the 82 treated patients had PH and improved after 
discontinuation of therapy. Our patient showed clinical and echocardiographic signs of 
PH after a few days of thalidomide therapy. In the described case reports, symptoms Case Rep Oncol 2011;4:487–489 
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occurred after a few months, but in the cohort described by Lafaras et al. [1], 2 patients 
showed subclinical PH 1 month after thalidomide administration. 
The etiology of PH in these patients is still unclear. Adverse effects of thalidomide 
should be considered in the absence of pulmonary embolism. Thalidomide possibly 
causes a vasodilator and vasoconstriction imbalance, which may cause abnormal 
pulmonary vascular response leading to a vicious circle perpetuating PH [8, 9]. A direct 
effect of thalidomide on the pulmonary endothelial cells could be postulated [5]. In the 
case described by Hattori et al. [6], autopsy revealed an extensive formation of plexogenic 
pulmonary arteries accompanied by thickening of intimae and media arteries. Lafaras et 
al. [1] indicate that the subgroup of MM patients with unknown heart disease (coronary 
artery disease, valvular heart disease and hypertension) receiving thalidomide should be 
thoroughly examined by echocardiography for the early detection of clinical and/or 
subclinical PH. 
Thus, echocardiographic evaluation might be necessary to all patients receiving 
thalidomide; it not only provides an estimate of pulmonary pressure but also may help to 
exclude any secondary causes of PH, predict the prognosis, monitor the efficacy of 
specific therapeutic interventions and detect the preclinical stage of the disease [1]. 
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